Publication

学会発表など  →Presentations' list

 

Hanada K, Akazawa M. CURRENT STATUS OF REAL WORLD DATA USING FOR CONDUCTING COST-EFFECTIVENESS ASSESSMENTS IN JAPAN. ISPOR Asia-Pacific Conference, Tokyo, Japan. Poster Presentation. Sep 11, 2018.

 

Noto S, Fukuda T, Saito S, Shimozuma K, Ikeda S, Shiroiwa T, Igarashi A, Ishida H, Moriwaki K, Kobayashi M. PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE FOR HEART DISEASE PATIENTS IN JAPAN. ISPOR Asia-Pacific Conference, Tokyo, Japan. Poster Presentation. Sep 11, 2018.

 

Inoue S, Kobayashi M, Pang F. AN ECONOMIC EVALUATION OF MIGALASTAT VERSUS ERT FOR THE TREATMENT OF FABRY DISEASE IN JAPAN. ISPOR Asia-Pacific Conference, Tokyo, Japan. Poster Presentation. Sep 10, 2018.

 

Kamae I, Kitamura A, Sakurai M, Yamamoto M, Inoue S, Shibahara H, Kobayashi M. ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN JAPAN. ISPOR Asia-Pacific Conference, Tokyo, Japan. Poster Presentation. Sep 9, 2018.

 

Kitamura A, Sato T, Priest V, Inoue S, Kobayashi M. COST-MINIMIZATION ANALYSIS OF VERCISE DBS SYSTEM FOR PARKINSON'S DISEASE IN JAPAN. ISPOR Asia-Pacific Conference, Tokyo, Japan. Poster Presentation. Sep 9, 2018.

 

Kamae I, Kobayashi M, Patel P, Neumann PJ. Japanese HTA and Pricing: Current Methods and Future Potential. ISPOR Asia-Pacific Conference, Tokyo, Japan. Workshop Presentation. Sep 10, 2018.

 

Ikeda S, Kobayashi M, Wong-Rieger D. How Will Patient Centricity Be Captured in the Japanese HTA and Healthcare Reform? ISPOR Asia-Pacific Conference, Tokyo, Japan. Issue Panel Presentation. Sep 9, 2018.

 

Kim S, Kobayashi M, Xuan j, Ko B. REAL-WORLD EVIDENCE AND LOCAL EVIDENCE GENERATION: HOW SHOULD IT BE APPROACHED IN ASIA PACIFIC? ISPOR 2018 Baltimore, MD, USA. 22th May, 2018.

 

Xuan J, Liu L, Kobayashi M, Lee S. ADVANCING PATIENT ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES IN ASIA – THE ROLE OF REAL-WORLD DATA IN THE VALUE FRAMEWORK. ISPOR 2018 Baltimore, MD, USA. 21th May, 2018

 

Kobayashi M. The trial intorduction of cost-effectiveness evaluation and future prospects in japan. 5th seminar of the center of pharmacoeconomics and QOL research at Niigata University of health and welfare. Niigata University of health and welfare, Niigata, Japan. 10th Mar, 2018. (in Japanese)

 

Murata T, Suzukamo Y, Shiroiwa T, Shimozuma K, Ohashi Y, Mukai H. Response shift analysis of QOL in SELECT-BC using Taxane and TS-1 for metastasis and recurrent breast cancer patients. 5th QOL/PRO research academic meeting, Okayama, Japan. Dec 2, 2017.

 

Mishina S, Murata T. Medical Cost Evaluation of Apixaban versus Warfarin in Patients with Non valvular Atrial Fibrillation: Japanese Claims Database Analysis. ISPOR 20th Annual European Congress Glasgow, Scotland. Research Poster Presentations. Nov 4-8, 2017.

 

Yamabe K, Kuwabara H, Inoue S, Kobayashi M. Burden Of Ulcerative Colitis In Japan. ISPOR 20th Annual European Congress Glasgow, Scotland. Research Poster Presentations. Nov 6, 2017.

 

Kobayashi K, Kanda H, Shimazaki R, Murata T, Kobayashi M. Economic Evaluation of Egfr Control In Patients With Chronic Kidney Disease In Japan. ISPOR 20th Annual European Congress Glasgow, Scotland. Research Poster Presentations. Nov 6, 2017.

 

Noto S, Igarashi A, Shiroiwa T, Fukuda T, Ikeda S, Moriwaki K, Saito S, Shimozuma K, Ishida H, Kobayashi M. Reliability And Validity Of Two Proxy Versions Of EQ-5D-5L In Japan. ISPOR 20th Annual European Congress Glasgow, Scotland. Research Poster Presentations. Nov 7, 2017.

 

Noto S, Izumi R, Moriwaki K, Shiroiwa T, Igarashi A, Fukuda T, Ikeda S, Saito S, Shimozuma K, Ishida H, Kobayashi M. Comparison Between Eq-5d And Hui In Japanese Population Norms. ISPOR 20th Annual European Congress Glasgow, Scotland. Nov 4-8, 2017.

 

Yamabe K, Inoue S, Kuwabara H, Kobayashi M. Cost-Effectiveness Analysis For Treatment Of Parkinson’s Disease: A Systematic Review. ISPOR 19th Annual European Congress Glasgow, UK. Nov 4-8, 2017.

 

Noto S, Sengoku A, Nomi M, Murata T, Kato S. Relationship between bowel dysfunction and health-related QOL in patients with spinal cord injury. The 51st Japanese Cvvupational Therapy Congress & Expo. 22-24 September, 2017.

 

Seno A, Yin C, Metz L, Ghosh SK, Murata T, Kobayashi M. The treatment effect on early stage hepatocellular carcinoma in Japanese population: Literature review. ISPOR 22nd Annual International Meeting Boston USA. Research Poster Presentations. May 22, 2017.

 

Okumura H, Inoue S, Naidoo S, Holmstrom S, Akaza H. Cost-effectiveness analysis of enzalutamide for patients with pre-metastatic castration-resistant prostate cancer. The 105th Annual Meeting of the Japanese Urological Association. April 21-24, 2017.

 

Nitta K, Sugiyama K, Wajima R, Tachibana M, Inoue S, Daitou T, Kurashima H. Study on the forecas of risk of suffering severe vision disability with primary open angle Glaucoma(broadly defined). The 121st Annual Meeting of the Japanese Ophthalmological Sciety. April 6-9, 2017.

 

Wang F, Murata T, Izumi N, Kida M, Horblyuk R, Terayama Y. Bleeding risk among Japanese non-valvular atrial fibrillation patients initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin in the real world. American College of Cardiology. March 18, 2017.

 

Kobayashi M. The trial intordoction of cost-effectiveness evoluation and future prospects in japan. 4th seminar of the center of pharmacoeconomics and QOL research at Niigata University of health and welfare. Niigata University of health and welfare, Niigata, Japan. 4th Mar, 2017. (in Japanese).

 

Nitta K, Wajima R, Tachibana G, Inoue S, Ohigashi T, Kurashima H, Sugiyama K. Predicting Lifetime Transition Risk Of Severe Visual Field Defect Using The Monte Carlo Simulation In Japanese Primary Open-Angle Glaucoma Patients. WGC2017 Helsinki, Finland, June 28- July 1, 2017.

 

Okumura H, Inoue S, Naidoo S, Holmstrom S, Akaza H. Cost-effectiveness analysis of enzalutamide for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer in Japan. ISPOR 22nd Annual International Meeting, Boston, Massachusetts, USA, May 20–24, 2017.

 

Nitta K, Inoue S, Fujiwara R, Daito T, Sugiyama K. Study on the forecast formula of suffering severe vision disability withbroadly defined primary open angle Glaucoma. The 27th Meeting of Japan Glaucoma Society. 17-19 September 2016.

 

Yamabe K, Inoue S, Kuwabara H, Kobayashi M. Cost-effectiveness analysis for treatment of parkinson’s disease: A systematic review. ISPOR 19th Annual European Congress, Vienna, Austria. 29 October-2 November 2016.

 

Okubo Y, Tsuruta D, Tang A, Inoue S, Itakura H, Hanada T, Otsuki M. Research about gap of treatment goals between doctors’ groups and psoriasis patients’ groups in Japan. The 115th Annual Meeting of the Japanese Dermatological Association. June 3-5, 2016.

 

Uda A, Hiroi S, Inoue S, Kuwabara H, Yamabe K, Otake K. Study on Patient-Reported Outcomes in Inflammatory Bowel Disease Treatment: A Systematic Review of the Literature. HTAi2016, Tokyo, Japan. 10-14 May, 2016.

 

Nitta K, Wajima R, Tachibana G, Inoue S, Fujiwara R, Sugiyama K. Analysis of Risk Factors for Visual Field Progression in Open Angle Glaucoma. ARVO2016, Seattle, WA, USA. 1-5 May, 2016.

 

Kobayashi M. The Whole picture of cost-efectiveness evaluation in japan. 3th seminar of the center of pharmacoeconomics and QOL research at Niigata University of health and welfare. Niigata University of health and welfare, Niigata, Japan. 5th Mar, 2016. (in Japanese).

 

Yuasa A, Ii Y, Yamamoto Y, Kitazaki S, Murata T, Saito K, Fujimoto Y. Outcome Research To Investigate The Actual Status of MRSA Infection and Usage of ANTI-MRSA Drugs in Real Clinical Settings in Japan : A Retrospective Database Study. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

 

Ikeda S, Murata T, Kobayashi M. Role of cost-effectiveness analysis in pricing process of new drug in Japan. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

 

Yamabe K, Hiroi S, Inoue S, Kobayashi M. Study on Cost-Effectiveness Analysis for Treatment of Major Depression Disease: A Systematic Review of Literature from 2004-2014. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

 

Yamabe K, Hiroi S, Inoue S, Kobayashi M. Study on Cost-Effectiveness Analysis for Ulcerative Colitis Treatment: A Systematic Review of Literature from 2004-2014. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

 

Yamabe K, Hiroi S, Inoue S, Kobayashi M. Study on Cost-Effectiveness Analysis for Multiple Myeloma Treatment:A Systematic Review of Literature from 2004-2014. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

 

Yamabe K, Inoue S, Hiroshima C. Epidemiology and Burden of Multiple Myeloma in Japan: A Systematic Review. ISPOR 18th Annual European Congress, Milan, Italy. 7-11 November, 2015.

 

Igarashi A, Fukuda T, Kobayashi M, Noto S, Saito S, Shimozuma K, Shiroiwa T, Ikeda S. Development of a national tariff for EQ-5D-5L in Japan. 32nd EuroQOL plenary meeting, Krakov, Poland. 10 Sep, 2015.

 

Okubo Y, Tsuruta D, Tang A, Inoue S, Chujyo K, Hagimori K, Otsuki M. Research about gap of treatment goals between doctors and psoriasis patients in Japan. The 30th Annual Meeting of the Japanese Society for Psoriasis Research. Sep 4-5, 2015.

 

Murata T, The investigation by the discrete choice experiment law on preference and willingness to pay of intermittent urinary catheters in patients with dysuria caused by neurogenic bladder. ISPOR Japan Chapter 11th Annual Meeting, Tokyo, Japan. 30th August, 2015. (in Japanese)

 

Ikeda S, Inoue S, Kobayashi M. Cost-effectiveness Analysis of Condoliase in Patients with Lumber Disc Herniation in Japan. ISPOR 20th Annual International Meeting, May 16-20 2015, Philadelphia, PA, USA


Sugimoto T, Kamae I, Yamabe K, Kobayashi M. Assessing the quality of health economic evaluations published in a Japanese setting: a systematic review of the literature for 1991-2012. ISPOR 20th Annual International Meeting. May 16-20, 2015, Philadelphia, PA, USA.


Kobayashi M. The actual techniques of modelling analysis in Japan. Center for Health Economics & QOL Research, Niigata University of Health and Welfare. Niigata, Japan.21th Feb, 2015. (in Japanese)


Murata T, Hanada K, Shibahara H. Claims database analysis of patients with chronic hepatitis C in Japan. 17th ISPOR Annual European Congress, 10th November 2014, Amsterdam, Netherlands.


McEwan P, Ward T, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Inoue S,Tang A, Kumada H. Estimating projected costs and quality-adjusted life expectancy associated with Daclatasvir plus Asunaprevir in difficult to treat Japanese patients chronically infected with HCV Genotype 1b. The annual AASLD liver meeting, 7-11 November 2014, Boston, USA.


Kamae I, Ward T, Webster S, Kobayashi M, McEwan P, Kalsekar A, Yuan Y, Inoue S, Tang A, Kumada H. Investigating treatment strategies to optimize clinical outcomes associated with emerging therapies for HCV. APASL, Asian Pacific Association for The Study of the Liver. Brisbane, Australia,2014.


Kamae I, Ward T, Webster S, Kobayashi M, McEwan P, Yuan Y, Kalsekar A, Inoue S, Tang A, Kumada H. Estimating the long-term clinical and economic outcomes of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b virus. APASL, Asian Pacific Association for The Study of the Liver. Brisbane, Australia.2014.


Sugiyama N, Murata T, Morishima Y, Fukuma Y, Shibasaki Y, Bidad C, Harnett J, Marshall L, Coindreau JL. Cost-effectiveness of biologics for rhumatoid arthritis patients: a real-world analsis of nationwide Japanese claims data. EULAR 2014, 11-14 June 2014, Paris, France.


Shibahara H, Shiroiwa T, Tange C, Nakamura K, Ozono S, Shimozuma K. Reanalysis of cost-effectiveness of abiraterone acetate as seconed line treatment for metasttic castration-resistant prostate cancer in Japan using a Japanese claim data set. 19th ISPOR Annual International Meeting, 2nd June 2014, Montreal, QC, Canada.


Kohno S, Ohno T, Murata T, Tateda K. Risk factors for the development of pneumonia: analysis of Japanese claims data. The 54th Annual meeting of the Japanese respiratory society. Osaka, Japan. April 25-27th ,2014. (in Japanese)


Kobayashi M. The present conditions and problem of claims data study in Japan. Center for Health Economics & QOL Research, Niigata University of Health and Welfare. Niigata, Japan.25th Jan, 2014. (in Japanese)

series  →Series' list

Kobayashi M. Value-based Approach [17] Health economics evaluation of Orphan Drug Orphan Drug is less evidence and also have different side from general medicine. 2018; 9:69-71. (in Japanese)

 

Kobayashi M. Value-based Approach [16] To be possible verifying hypothesis by utilizing the open data of NDB How to play RWD.Monthly Medical Information Express. 2018; 8:73-75. (in Japanese)

 

Kobayashi M. Value-based Approach [15] Possibility and limit of RWD We can play RWD. Monthly Medical Information Express. 2018; 7:73-75. (in Japanese)

 

Kobayashi M. Value-based Approach [14] Real Word Data The possibility to open by utilization of RWD. Monthly Medical Information Express. 2018; 6:75-77. (in Japanese)

 

Kobayashi M. Value-based Approach [13]  Cost-effectiveness evaluation The result change in the main constitution. Whose money do you spend? Monthly Medical Information Express. 2018; 5:64-66. (in Japanese)

 

Kobayashi M. Value-based Approach [12] Evaluate unexpectedly every cost. Do you evaluate neatly burden of disease? Monthly Medical Information Express. 2018; 4:76-79. (in Japanese)

 

Kobayashi M. Value-based Approach [11] Be aware of invisible cost! Decline of labor productivity. Monthly Medical Information Express. 2018; 3:66-68. (in Japanese)

 

Kobayashi M. Learning from scratch. Introduction of "Cost-effectiveness evaluation". Monthly Medical Information Express. 2018; 2:52-55. (in Japanese)

 

Kobayashi M. Value-based Approach [10] Value Evaluation of convenience and usability (5) A case of WTP research on Discrete Choice Experiment(DCE). Monthly Medical Information Express. 2018; 1:72-75. (in Japanese)

 

Kobayashi M. Value-based Approach [9] Value Evaluation of convenience and usability (4) Medical drugs' additional value can be evaluated by using amount of willingness to pay. Monthly Medical Information Express. 2017; 12:64-67. (in Japanese)

 

Kobayashi M. Value-based Approach [8] Value Evaluation of convenience and usability (3) Can medical devices be evaluated in the same approach? Monthly Medical Information Express. 2017; 11:64-66. (in Japanese)

 

Kobayashi M. Value-based Approach [7] Value Evaluation of convenience and usability (2) What is process utility? Monthly Medical Information Express. 2017; 10:64-66. (in Japanese)

 

Kobayashi M. Value-based Approach [6] Value Evaluation of convenience and usability (1) Considering the influence the added value of Health Technology Assessment. Monthly Medical Information Express. 2017; 9:72-74. (in Japanese)

 

Kobayashi M. Value-based Approach [5] Value Evaluation for circulatory organ disorder~Value Assessment of ACC/AHA. Monthly Medical Information Express. 2017; 8:68-70. (in Japanese)

 

Kobayashi M. Value-based Approach [4] Value Evaluation of anti-cancer drugs in USA~DrubAbacus and NCCN Evidence Blocks. Monthly Medical Information Express. 2017; 7:64-66. (in Japanese)

 

Kobayashi M. Value-based Approach [3] EXMO-MCBS: Analyzing how HTA would affect oncologic drugs. Monthly Medical Information Express. 2017; 6:58-60. (in Japanese)

 

Kobayashi M. Value-based Approach [2] ASCO Value Framework: What is the effect on price negotiation of oncologic drugs. Monthly Medical Information Express. 2017; 5:58-60. (in Japanese)

 

Kobayashi M. Value-based Approach [1] Change on drug price negotiation: Crumbling “Pricing from affordability method.”. Monthly Medical Information Express. 2017; 4:64-66. (in Japanese)

 

Kobayashi M. The essence of Pharmacoeconomics [91] Final episode. Monthly Medical Information Express. 2016; 7:86-89. (in Japanese)

 

Kobayashi M. The essence of Pharmacoeconomics [90] Using Excel to build the Model (6) The cost-effectiveness analysis of Markov model. Monthly Medical Information Express. 2016; 6:86-89. (in Japanese)

 

Kobayashi M. The essence of Pharmacoeconomics [89] Using Excel to build the Model (5) The basic of Markov model. Monthly Medical Information Express. 2016; 5:88-91. (in Japanese)

 

Kobayashi M. The essence of Pharmacoeconomics [88] Using Excel to build the Model (4) Sensitivity analysis. Monthly Medical Information Express. 2016; 3:88-91. (in Japanese)

 

Kobayashi M. The essence of Pharmacoeconomics [87] Using Excel to build the Model (3) Assessment of cost effectiveness. Monthly Medical Information Express. 2016; 2:76-79. (in Japanese)

 

Kobayashi M. The essence of Pharmacoeconomics [86] Using Excel to build the Model (2) Cost-effective analysis by using decision Tree. Monthly Medical Information Express. 2016; 1: 86-89. (in Japanese)

 

Kobayashi M. The essence of Pharmacoeconomics [85] Using Excel to build the Model (1) Decision Tree. Monthly Medical Information Express. 2015; 12:80-83. (in Japanese)

 

Kobayashi M. The essence of Pharmacoeconomics [84] Making the organization and human resource of Pharmacoeconomics (10) In-company training (ISPOR Movie Program). Monthly Medical Information Express. 2015; 11:78-81. (in Japanese)

 

Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [83] 【Special issue】Only this much! Pharmacoeconomics. Monthly Medical Information Express. 2015; 10:86-89. (in Japanese)

 

Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [82] Making the organization and human resource of Pharmacoeconomics (9) In-company training (skill level of Pharmacoeconomics ) Monthly Medical Information Express. 2015; 9:88-91. (in Japanese)

 

Kobayashi M.The essence of pharmacoeconomics: what is a price commensurate with value? [81] Pharmacoeconomics ~Is it a challenge or chance?~ Monthly Medical Information Express. 2015; 8:86-89. (in Japanese)

 

Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [80] Making the organization and human resource of Pharmacoeconomics (8) Affairs of HEOR department④ Monthly Medical Information Express. 2015; 7:86-89. (in Japanese)

 

Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [79] Making the organization and human resource of Pharmacoeconomics (7) Affairs of HEOR department③ Monthly Medical Information Express. 2015; 6:84-87. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [78] Making the organization and human resource of Pharmacoeconomics (6) Affairs of HEOR department② Monthly Medical Information Express. 2015; 5:78-81. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [77] Making the organization and human resource of Pharmacoeconomics (6) Affairs of HEOR department① Monthly Medical Information Express. 2015; 4:84-87. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [76] Making the organization and human resource of Pharmacoeconomics (5) Learning tool for pharmacoeconomics. Monthly Medical Information Express. 2015; 3:84-87. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [75]: Creating organizations and personnel in Pharmacoeconomics (4)Making the organization of HEOR. Monthly Medical Information Express. 2015; 2:86-89. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [74]: Creating organizations and personnel in Pharmacoeconomics (3)The project of cost-effectiveness analysis. Monthly Medical Information Express. 2015; 1:82-85. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [73]: Creating organizations and personnel in pharmacoeconomics (2) Role of the HEOR Division. Monthly Medical Information Express. 2014; 12: 84-87. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [72]: Creating organizations and personnel in pharmacoeconomics (1) Creating organizations. Monthly Medical Information Express. 2014; 11: 78-81. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [71]: ISPOR and the 6th Asia-Pacific Conference. Monthly Medical Information Express. 2014; 10:78-81. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [70]: Pharmacoeconomics remade (12): Probabilistic sensitivity analysis. Monthly Medical Information Express. 2014; 9:78-81. (in Japanese)


Kobayashi M. The essence of pharmacoeconomics: what is a price commensurate with value? [69]: Pharmacoeconomics remade (11): Sensitivity analysis. Monthly Medical Information Express. 2014; 8:78-81. (in Japanese)

Books  →Books' list

Inoue S. Chapter 6. Health care, economic and value of self-injection, dropping to the doctors and the patient needs and product development for the valuation of self-injection. Self-injection to think from Section 2 medical economic point of view medical fee points. (Regulatory Science).2016. (in Japanese)

 

Inoue S. Chapter7 The basics and the capture method of medicine charge, the medical insurance system in Japan Section4 Application of the medical economic evaluation in the medicine charge negotiations of the new medicine. World Medicine charge 2015. 2015; Page.326-329. (in Japanese)


Kobayashi M. Model analysis in the medical economic evaluation. Basic medical economic evaluation -to understand cost-effectiveness definitely- (Regulatory Science).2015, Page.103-125.(in Japanese)


Kobayashi M. Specific method of utilizing Pharmacoeconomics. Technical Information Institute co,. LTD. (Nagase T et al eds). 2014. (in Japanese).2014.


Inoue S. Development strategy on the basis of the real condition and clinical condition, a mechanism of the treatment of sepsis. Technical Information Institute co,. LTD. (Hayakawa M et al eds). 2013. (in Japanese)


Inoue S. Chapter 9 The evaluation of a value and the price using the drug economics in the pre-filled syringe preparation. Material demand characteristics and inferior quality improvement of the pre-filled syringe preparation. Science & technology Co.,Ltd. (Shiraishi Y et al. eds). 2012. (in Japanese)


Kobayashi M. What is demanded now? A medical risk and quantitative approach. Medical risk management knowledge book. Japan Medical Publisher, Mano T. 2006, p.23-45. (in Japanese)


Kobayashi M. Chapter5 Model analysis for clinical economics. Medical technology/Pharmaceutical products. (Keiso Shobo, Ikegami N, Nishimura S eds.) 2005; p.102-192. (in Japanese)


Kobayashi M. Chapter2 Why is trust not obtained? 1. Questionnaire results analysis about the choice of the medical institution. Hospital management of the trust recovery. (YAKUJI NIPPO LIMITED, Mano T ed) . 2005; p.25-35. (in Japanese)


Kobayashi M. Technology assessment and medical management-In case of pharmacoeconomics Medical management of the 21th century.( YAKUJI NIPPO LIMITED, Mano T ed) 2003; p.287-304. (in Japanese)